CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 140 enrolled
Drug / intervention
MOVIPREPdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01732692
NCT01732692Phase 3Completed

Multicenter Endoscopist-blinded Randomized Parallel-group Comparative Study to Assess Efficacy, Safety and Tolerance of Morning-only Dosing Compared to Control Split-dosing With Nocturnal Pause in MOVIPREP® Bowel Preparation Prior to Colonoscopy

Takeda·interventional·Posted Nov 26, 2012·Updated May 15, 2014

In Brief

A Phase 3 clinical trial evaluating MOVIPREP for Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.. Completed, enrolled 140 participants across 3 sites in 2 countries.

Detailed Summary

To compare colon cleansing quality induced by the 2 different modes of MOVIPREP® intake in 5 colon segments prior to colonoscopy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesKazakhstan, Russia
CollaboratorsNorgine BV

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2012
Enrollment StartNov 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.6 years ago

Interventions

MOVIPREPdrug

MOVIPREP solution